{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:23:36Z","timestamp":1790799816830,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ajpath.2019.08.002","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T19:16:41Z","timestamp":1567192601000},"page":"2138-2148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["The Role of MET in Melanoma and Melanocytic Lesions"],"prefix":"10.1016","volume":"189","author":[{"given":"Yan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7313-514X","authenticated-orcid":false,"given":"Kyu Young","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Giubellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2019.08.002_bib1","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ajpath.2019.08.002_bib2","first-page":"106","article-title":"Cancer statistics, 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ajpath.2019.08.002_bib3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2019.08.002_bib4","series-title":"WHO Classification of Skin Tumours","first-page":"66","article-title":"Melanocytic tumours: introduction","author":"Elder","year":"2018"},{"key":"10.1016\/j.ajpath.2019.08.002_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ajpath.2019.08.002_bib6","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2019.08.002_bib7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2019.08.002_bib8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajpath.2019.08.002_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2019.08.002_bib10","doi-asserted-by":"crossref","first-page":"17795","DOI":"10.18632\/oncotarget.14855","article-title":"MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor","volume":"8","author":"Caenepeel","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ajpath.2019.08.002_bib11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.biopha.2017.01.045","article-title":"A mini-review of c-Met as a potential therapeutic target in melanoma","volume":"88","author":"Al-U'datt","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ajpath.2019.08.002_bib12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1042\/BST20160132","article-title":"Targeting the hepatocyte growth factor\/Met pathway in cancer","volume":"45","author":"De Silva","year":"2017","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.ajpath.2019.08.002_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejca.2017.10.014","article-title":"Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial","volume":"87","author":"Sch\u00f6ffski","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajpath.2019.08.002_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2019.08.002_bib15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1126\/science.1846706","article-title":"Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product","volume":"251","author":"Bottaro","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2019.08.002_bib16","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Met, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ajpath.2019.08.002_bib17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/342440a0","article-title":"Molecular cloning and expression of human hepatocyte growth factor","volume":"342","author":"Nakamura","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2019.08.002_bib18","first-page":"2962","article-title":"Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing","volume":"11","author":"Rodrigues","year":"1991","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ajpath.2019.08.002_bib19","doi-asserted-by":"crossref","first-page":"12039","DOI":"10.1073\/pnas.2034936100","article-title":"Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor\/scatter factor","volume":"100","author":"Gherardi","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2019.08.002_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/path.1711740308","article-title":"Detection of the c-met proto-oncogene product in normal skin and tumours of melanocytic origin","volume":"174","author":"Saitoh","year":"1994","journal-title":"J Pathol"},{"key":"10.1016\/j.ajpath.2019.08.002_bib21","first-page":"2195","article-title":"Met and hepatocyte growth factor\/scatter factor signal transduction in normal melanocytes and melanoma cells","volume":"7","author":"Halaban","year":"1992","journal-title":"Oncogene"},{"key":"10.1016\/j.ajpath.2019.08.002_bib22","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1073\/pnas.93.12.5866","article-title":"Scatter factor\/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development","volume":"93","author":"Takayama","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2019.08.002_bib23","doi-asserted-by":"crossref","first-page":"14140","DOI":"10.1074\/jbc.M611563200","article-title":"Up-regulation of MET expression by alpha-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis","volume":"282","author":"Beuret","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2019.08.002_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-0749.1999.tb00503.x","article-title":"Hepatocyte growth factor\/scatter factor-MET signaling in neural crest-derived melanocyte development","volume":"12","author":"Kos","year":"1999","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.ajpath.2019.08.002_bib25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.tcb.2009.07.002","article-title":"Crosstalk in Met receptor oncogenesis","volume":"19","author":"Lai","year":"2009","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.ajpath.2019.08.002_bib26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1755-148X.2011.00836.x","article-title":"Receptor tyrosine kinases and their activation in melanoma","volume":"24","author":"Easty","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ajpath.2019.08.002_bib27","first-page":"5157","article-title":"c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype","volume":"58","author":"Otsuka","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2019.08.002_bib28","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1038\/ncomms4116","article-title":"Kinase fusions are frequent in Spitz tumours and spitzoid melanomas","volume":"5","author":"Wiesner","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2019.08.002_bib29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.cll.2017.05.003","article-title":"Toward a molecular-genetic classification of spitzoid neoplasms","volume":"37","author":"Tetzlaff","year":"2017","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.ajpath.2019.08.002_bib30","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1038\/ncomms8174","article-title":"Activating MET kinase rearrangements in melanoma and Spitz tumours","volume":"6","author":"Yeh","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2019.08.002_bib31","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-06-0776","article-title":"c-Met is a potentially new therapeutic target for treatment of human melanoma","volume":"13","author":"Puri","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2019.08.002_bib32","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","article-title":"The genetic evolution of melanoma from precursor lesions","volume":"373","author":"Shain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2019.08.002_bib33","doi-asserted-by":"crossref","first-page":"8125","DOI":"10.1038\/sj.onc.1205034","article-title":"Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development","volume":"20","author":"Li","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.ajpath.2019.08.002_bib34","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/bjc.1993.422","article-title":"Expression of the c-Met\/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression","volume":"68","author":"Natali","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2019.08.002_bib35","doi-asserted-by":"crossref","first-page":"533","DOI":"10.18632\/oncoscience.161","article-title":"Retrospective review of MET gene mutations","volume":"2","author":"Zenali","year":"2015","journal-title":"Oncoscience"},{"key":"10.1016\/j.ajpath.2019.08.002_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.ajpath.2019.08.002_bib37","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-06-0250","article-title":"c-Met ectodomain shedding rate correlates with malignant potential","volume":"12","author":"Athauda","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2019.08.002_bib38","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/gcc.20604","article-title":"Expression and mutational analysis of MET in human solid cancers","volume":"47","author":"Ma","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ajpath.2019.08.002_bib39","doi-asserted-by":"crossref","first-page":"E56","DOI":"10.1002\/ijc.26487","article-title":"Association of activated c-Met with NRAS-mutated human melanomas","volume":"131","author":"Chattopadhyay","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2019.08.002_bib40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ajpath.2019.08.002_bib41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1023\/A:1006596909948","article-title":"C-met activation is necessary but not sufficient for liver colonization by B16 murine melanoma cells","volume":"16","author":"Lin","year":"1998","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ajpath.2019.08.002_bib42","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-08-4889","article-title":"Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases","volume":"69","author":"Qian","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2019.08.002_bib43","first-page":"7345","article-title":"A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in\u00a0vitro and exhibits cytoreductive antitumor activity in\u00a0vivo","volume":"63","author":"Christensen","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2019.08.002_bib44","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/1535-7163.MCT-13-0499","article-title":"Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model","volume":"12","author":"Surriga","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ajpath.2019.08.002_bib45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fonc.2015.00031","article-title":"Phenotype switching in melanoma: implications for progression and therapy","volume":"5","author":"Li","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajpath.2019.08.002_bib46","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1158\/0008-5472.CAN-06-3481","article-title":"A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis","volume":"67","author":"Alonso","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2019.08.002_bib47","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ccr.2013.08.018","article-title":"A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma","volume":"24","author":"Caramel","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2019.08.002_bib48","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1755-148X.2010.00807.x","article-title":"The cadherin switch in melanoma instigated by HGF is mediated through epithelial-mesenchymal transition regulators","volume":"24","author":"Koefinger","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ajpath.2019.08.002_bib49","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1038\/sj.emboj.7601213","article-title":"Hepatocyte growth factor induces cell scattering through MAPK\/Egr-1-mediated upregulation of Snail","volume":"25","author":"Grotegut","year":"2006","journal-title":"EMBO J"},{"key":"10.1016\/j.ajpath.2019.08.002_bib50","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/sj.onc.1208318","article-title":"HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1","volume":"24","author":"Gaggioli","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ajpath.2019.08.002_bib51","first-page":"3783","article-title":"The role of CD44 in epithelial-mesenchymal transition and cancer development","volume":"8","author":"Xu","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ajpath.2019.08.002_bib52","first-page":"1576","article-title":"Hepatocyte growth factor\/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1","volume":"63","author":"Recio","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2019.08.002_bib53","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cyto.2015.12.013","article-title":"The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: diverse roles in modulating immune cell functions","volume":"82","author":"Ilangumaran","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.ajpath.2019.08.002_bib54","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nature14407","article-title":"MET is required for the recruitment of anti-tumoural neutrophils","volume":"522","author":"Finisguerra","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2019.08.002_bib55","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.immuni.2017.09.012","article-title":"Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy","volume":"47","author":"Glodde","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.ajpath.2019.08.002_bib56","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.15252\/embr.201744075","article-title":"Identification of a novel population of highly cytotoxic c-Met-expressing CD8(+) T lymphocytes","volume":"18","author":"Benkhoucha","year":"2017","journal-title":"EMBO Rep"},{"key":"10.1016\/j.ajpath.2019.08.002_bib57","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0092-8674(01)00567-0","article-title":"A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth","volume":"107","author":"Trusolino","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2019.08.002_bib58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2019.08.002_bib59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2019.08.002_bib60","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and immune evolution of melanoma acquiring MAPKi resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2019.08.002_bib61","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nature11249","article-title":"Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors","volume":"487","author":"Wilson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2019.08.002_bib62","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1158\/1078-0432.CCR-15-1762","article-title":"Personalized preclinical trials in BRAF inhibitor-resistant patient-derived xenograft models identify second-line combination therapies","volume":"22","author":"Krepler","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2019.08.002_bib63","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2019.08.002_bib64","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1535-7163.MCT-15-0963","article-title":"Hypoxia-driven mechanism of vemurafenib resistance in melanoma","volume":"15","author":"Qin","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ajpath.2019.08.002_bib65","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/bjc.2016.419","article-title":"Phase II randomised discontinuation trial of the MET\/VEGF receptor inhibitor cabozantinib in metastatic melanoma","volume":"116","author":"Daud","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2019.08.002_bib66","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/14728222.2012.680957","article-title":"Targeting the HGF\/MET signaling pathway in cancer therapy","volume":"16","author":"Cecchi","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.ajpath.2019.08.002_bib67","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1158\/1078-0432.CCR-10-3169","article-title":"Therapeutic implications of the emerging molecular biology of uveal melanoma","volume":"17","author":"Patel","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2019.08.002_bib68","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10637-014-0167-5","article-title":"Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors","volume":"33","author":"Puzanov","year":"2015","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ajpath.2019.08.002_bib69","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(18)30146-3","article-title":"Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study","volume":"19","author":"Rimassa","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944019307035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944019307035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T16:34:32Z","timestamp":1757694872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944019307035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":69,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0002944019307035"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2019.08.002","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of MET in Melanoma and Melanocytic Lesions","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2019.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}